Recent news on Rapamune

Enticing cells to 'eat' Huntington's  -  May 8, 2007
BiopharmaReporter.com,Prof Rubinsztein first discovered that an existing immunosuppressant drug, namely Wyeth's Rapamune (rapamycin/sirolimus), induced autophagy in mice and

CYPHER(R) Sirolimus-Eluting Coronary Stent Had Similar Results to ...  -  May 22, 2007
Earthtimes.orgSirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R).

Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to ...  -  May 22, 2007
PharmaLive.com (press release),Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R).

Changing Heart Transplant Drugs Could Boost Kidney Function  -  Apr 26, 2007
Atlanta Journal Constitution (subscription),Their research received funding from Wyeth Pharmaceuticals, which makes sirolimus (Rapamune). One four-year study of 78 heart transplant patients found that

Wyeth gets green light to reopen idled facility  -  May 10, 2007
Philadelphia Inquirer,Other products made at the plant include Protonix, Rapamune and Advil, the company said. In recent years, Wyeth said it also had built new "quality-control

ISHLT: In Cardiac Transplant, Switching Immunosuppessants Helps ...  -  Apr 26, 2007
MedPage Today,Weaning patients off calcineurin inhibitors such as tacrolimus (Prograf) and cyclosporine and on to sirolimus (Rapamune) improved renal function,

Changing Heart Transplant Drugs Could Boost Kidney Function  -  26 Apr 2007
Forbes,Their research received funding from Wyeth Pharmaceuticals, which makes sirolimus (Rapamune). One four-year study of 78 heart transplant patients found that

WeissComm Partners Announces Several New Hires to Strengthen and ...  -  Apr 23, 2007
PR Newswire (press release),Rapamune(R); and several products for GlaxoSmithKline, including Advair(R), for the treatment of asthma and chronic obstructive pulmonary disease,

CYPHER® Sirolimus-Eluting Coronary Stent Demonstrates Sustained ...  -  Apr 2, 2007
Medical News Today (press release),Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®.

MacuSight(TM) to Present at IBC's 4th International Conference on ...  -  Apr 10, 2007
PR Newswire (press release),As the active pharmaceutical ingredient in the FDA-approved products Rapamune(R) and CYPHER(R) Sirolimus-eluting Coronary Stent, sirolimus has been safely

Inspectors are finished with Wyeth drugmaking plant  -  Apr 5, 2007
Asbury Park Press,Wyeth also makes Rapamune, which prevents organ rejection after kidney transplants, Protonix, an acid reflux medicine, and several non-prescription drugs

CYPHER(R) Sirolimus-eluting Coronary Stent Had Similar Results To ...  -  27 Mar 2007
Medical News Today (press release),Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R).

Cordis Corporation to emphasize commitment to interventional ...  -  Mar 21, 2007
Prdomain Business Register (press release),Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®.

Culture May Stop The Slim Down in Overweight Black Women  -  Feb 28, 2007
BET,8, 2007 – The FDA has approved new dosing recommendations for the kidney transplant drug Rapamune, which now allow it to be used in conjunction with

Roche Against Switch in Immunosuppressant Regimen  -  Feb 23, 2007
Medscape (subscription)...in combination with CellCept (mycophenolate mofetil) to Rapamune (sirolimus) in combination with CellCept at 12 weeks post heart transplantation.

Roche warns against switch in immunosuppressant regimen for heart ...  -  Feb 23, 2007
TheHeart.Org,...immunosuppressant mycophenolate mofetil (MMF, CellCept), had been switched to a regimen of sirolimus (Rapamune, Wyeth Pharmaceuticals) plus MMF [1].

FDA Approves New Dosing Recommendations for RAPAMUNE in High ...  -  Feb 5, 2007
Drug Newswire (press release),RAPAMUNE is the first and only kidney transplant therapeutic with dosing recommendations specifically for the treatment of high immunologic risk renal

FDA says Roche cancels heart transplant study  -  Feb 22, 2007
Reuters...company's immunosupressant drug CellCept to the immunosupressant drug sirolimus and CellCept. Sirolimus is sold by Wyeth under the brand name Rapamune.

Cordis Corporation's manufacturing facility recognised with Shingo ...  -  Feb 9, 2007
Prdomain Business Register (press release),Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®.

Roche weathers a hard week  -  Feb 24, 2007
Monsters and Critics.com,...be achieved with the withdrawal of calcineurin inhibitor therapy followed by the introduction of Wyeth`s Rapamune, which is also known as sirolimus.

FDA approves new dosing for Wyeth drug  -  Feb 2, 2007
Boston Globe,MADISON, NJ --Drug developer Wyeth said Friday the US Food and Drug Administration approved new dosing recommendations for Rapamune, which is a kidney

Big dispute over tiny root  -  Feb 14, 2007
Chicago Daily Herald,...owned by Bristol-Myers Squibb Co. is taken from the bark of the yew tree, and Wyeth’s kidney transplant drug Rapamune comes from Easter Island soil.

(PRN) - CDI Corp. Schedules 2006 Fourth Quarter and Year-End ...  -  Feb 2, 2007
Bolsamania.com,...(PRN) - FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients ... [+]. (PRN) - 'Two Minute Warning' for

Research endeavors to make cancer treatment less expensive  -  Jan 30, 2007
49abcnews.com,They're testing rapamycin, marketed as Rapamune. The drug is already FDA approved to prevent kidney transplant rejection. But early studies show it may also

Relief Possible For High Costs Of Fighting Cancer  -  Jan 16, 2007
KDKA,Researchers in Chicago are testing rapamycin or rapamune, which is already FDA approved to prevent kidney transplant rejection.

Prospecting in the biosphere  -  Jan 13, 2007
Houston Chronicle,...owned by Bristol-Myers Squibb Co. is taken from the bark of the yew tree, and Wyeth's kidney transplant drug Rapamune comes from Easter Island soil.

Patent piracy  -  Jan 13, 2007
Online Athens (subscription),Wyeth's kidney transplant drug Rapamune comes from Easter Island soil. But bioprospecting is mostly unregulated and there are mounting calls to establish

Peruvian root in bioprospecting dispute  -  Jan 5, 2007
Boston Herald,...owned by Bristol-Myers Squibb Co. is taken from the bark of the yew tree, and Wyeth’s kidney transplant drug Rapamune comes from Easter Island soil.

Peruvian root in bioprospecting dispute  -  Jan 5, 2007
USA TodayTaxol owned by Bristol-Myers Squibb is taken from the bark of the yew tree, and Wyeth's kidney transplant drug Rapamune comes from Easter Island soil.

Peruvian root in bioprospecting dispute  -  Jan 5, 2007
The Westfall Weekly News,...owned by Bristol-Myers Squibb Co. is taken from the bark of the yew tree, and Wyeth‘s kidney transplant drug Rapamune comes from Easter Island soil.

Pharmacopeia's JAK3 Program Subject Of $189M Wyeth Deal  -  Jan 4, 2007
BioWorld Online,...based Amgen Inc.), and its transplant rejection franchise, which includes Rapamune. At this time, the JAK3 program is at the lead optimization stage.

The First Third-Generation Coronary Stent Approved For Use by ...  -  Dec 4, 2006
CNW Telbec (Communiqués de presse),Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R).

Data to Include Analyses on Diabetics, and Patients With Multiple ...  Nov 6, 2006
Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... -Yahoo! News (press release) CTI Announces Joseph M. McCafferty Has Joined as Vice President  Nov 7, 2006
While at Wyeth, Mr. McCafferty played an important role in the commercial growth of Rapamune in solid organ transplant, which has consistently exceeded market ... -PharmaLive.com (press release), Delivering on Nano's Promise  Oct 9, 2006
The first drug to be approved in the United States using NanoCrystal technology was a solid-dose formulation of the immunosuppressant Rapamune (sirolimus) from ... -Drug Discovery & Development, MacuSight(TM) Initiates Wet Age-Related Macular Degeneration Study  Oct 31, 2006
As the active pharmaceutical ingredient in the FDA-approved products Rapamune® and CYPHER® Sirolimus-eluting Coronary Stent, sirolimus has been safely ... -Yahoo! News (press release) Health Canada Endorsed Important Safety Information on Rapamune ...  Aug 25, 2006
Specifically this involves Rapamune® (sirolimus), mycophenolate mofetil, and corticosteroids, used in combination with interleukin-2 receptor antibody ... -DG News

Study in New England Journal of Medicine Suggests Heart Attack ...  Sep 13, 2006
Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a ... -PR Newswire

FDA panel to review safety of 16 drugs in children  -  Nov 15, 2006
MarketWatchOn Wyeth's Rapamune, the investigation found 19 pediatric cases of adverse events, including two reports of fluid collection that develops between the

Drug Takes Aim at Kidney Transplant Rejection  -  Nov 23, 2006
Ivanhoe,The study involved about 450 high-risk patients who were randomly assigned to receive sirolimus (Rapamune) and the standard anti-rejection drug tacrolimus

The First Third-Generation Coronary Stent Approved For Use by ...  -  Dec 4, 2006
CNW Telbec (Communiqués de presse),Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R).

Promising Treatment For High Risk Kidney Recipients In First Year ...  -  Nov 24, 2006
Medical News Today (press release),Sirolimus, marketed by Wyeth Pharmaceuticals as Rapamune®, is in a novel class of immunosuppressant agents called mammalian target of rapamycin (mTOR)

On Safety of 16 Drugs in Children  -  Nov 15, 2006
Wall Street Journal (subscription),GlaxoSmithKline PLC's Zofran and Avandia, Forest Laboratories Inc.'s Celexa, Novartis AG's Trileptal, Wyeth's Rapamune and Abbott Laboratories' Norvir.

Health Canada Endorsed Important Safety Information on Rapamune ...  Aug 25, 2006
Specifically this involves Rapamune® (sirolimus), mycophenolate mofetil, and corticosteroids, used in combination with interleukin-2 receptor antibody ... -DG News

Study Suggests CYPHER(r) Sirolimus-Eluting Coronary Stent More ...  Jul 31, 2006
Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a ... -PR Newswire UK

MacuSight Announces FDA Acceptance of IND for Novel Ophthalmic ...  Aug 8, 2006
As the active pharmaceutical ingredient in the FDA-approved therapeutics Rapamune® and the CYPHER® Sirolimus-eluting Coronary Stent, sirolimus has been ... -Yahoo! News

MacuSight Announces FDA Acceptance Of IND For Novel Ophthalmic ...  Aug 9, 2006
As the active pharmaceutical ingredient in the FDA-approved therapeutics Rapamune(R) and the CYPHER(R) Sirolimus-eluting Coronary Stent, sirolimus has been ... -Medical News Today

The Market for Immusuppresssants Used In Transplantation Is Set To ...  Jul 19, 2006
...followed by mTOR inhibitors. mTOR inhibitors are expected to be the fastest growing class, driven by Wyeths Rapamune. We foresees the ... -Genetic Engineering News

Data Show Overlapping CYPHER(R) Sirolimus-Eluting Coronary Stents ...  Jul 18, 2006
Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a ... -Medical News Today

Commercial Insight: Transplantation  Jun 29, 2006
...by mTOR inhibitors. mTOR inhibitors are expected to be the fastest growing class, driven by Wyeth's Rapamune. Datamonitor foresees ... -Pharmaceutical Business Review

Elan Signs License Agreement with Abbott for Elan's Proprietary ...  Jul 5, 2006
...utilize Elan's NanoCrystal Technology, including TriCor(R) (marketed by Abbott), Megace(R) ES (marketed by Par Pharmaceuticals) and Rapamune(R) (marketed by ... -Business Wire

Elan Signs License Agreement with Abbott for Elan's Proprietary ...  Jul 5, 2006
Rapamune(R) is a registered trademark owned by WyethPharmaceuticals. Crestor(R) is a registered trademark of the AstraZeneca group ofcompanies. ... -Finanzen.net



Study Suggests Drug-Eluting Stent Type and Vessel Size are ...  16 May 2006
Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... - Yahoo! News

Brain Pathway Signals Rats When To Eat  May 11, 2006
The opposite effect was also found: When satiated rats were given a well-known inhibitor of mTOR, the immune suppressant Rapamune (rapamycin), their intake of ... - MedPage Today

ASD - AGM STATEMENT  May 10, 2006
...particularly AxSYM BNP, which is used in the detection of heart failure, and also from the Abbott IMx assay for Wyeth`s anti-rejection drug sirolimus (Rapamune ... - TV2 Nettavisen





- The e-CYPHER(SM) Registry Manuscript Published in the Journal ...  Apr 3, 2006
Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a ... - ITNews

Cordis Corporation to Develop Global Cardiac and Vascular ...  Apr 4, 2006
Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... - Yahoo! News

Early confusion over Medicare plan ensnares many patients  Mar 14, 2006
After careful research, he decided on a Humana plan that promised to supply the medications, Prograf and Rapamune, which together cost nearly $2,500 a month. ... - Grand Forks Herald



SIROLIMUS REDUCES THE RISK OF CANCER IN KIDNEY TRANSPLANT  Feb 6, 2006
In this analysis of the Rapamune Maintenance Study, 430 kidney transplant patients were randomly assigned to remain on sirolimus (SRL), cyclosporine (CsA) and ... - ITNews,

The REALITY Trial and Accompanying Editorial Appear in Prestigious ...  Feb 21, 2006
Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... - Yahoo! News

Wyeth closing  Feb 16, 2006
...planned for 2007. That’s when production of Rapamune Liquid, Inderal LA and Premarin Cream will end in Rouses Point. In 2008, with ... - Plattsburgh Press Republican,

Sirolimus Reduces the Risk of Cancer in Kidney Transplant Patients  09 Feb 2006
...additional trials are therefore needed to confirm what are already promising results." Details of the study In this analysis of the Rapamune Maintenance Study ... - Canada NewsWire

CYPHER(R) Sirolimus-Eluting Coronary Stent Outperforms Taxus Stent ...  Feb 2, 2006
Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a ... - PR Newswire

Elan and EntreMed tie up technology deal  Jan 10, 2006
Other marketed pharmaceutical products in the US using the technology include Abbott's TriCor, Par Pharmaceutical's Megace and Wyeth's Rapamune. ... - RTE.ie

Wyeth posts 4Q profit of $731.7 million  Jan 31, 2006
Edwards & Sons. However, sales of immuno-suppressant Rapamune, used by kidney transplant patients, exceeded his estimates. Rauch said ... - BusinessWeek

Elan and EntreMed Execute License Agreement for Proprietary ...  Jan 10, 2006
...utilizing Elan's NanoCrystal Technology include TriCor(R) (marketed by Abbott), Megace(R) ES (marketed by Par Pharmaceuticals), and Rapamune(R) (marketed by ... - PharmaLive.com

Elan and EntreMed Execute License Agreement for Proprietary ...  Jan 9, 2006
...utilizing Elan's NanoCrystal Technology include TriCor® (marketed by Abbott), Megace® ES (marketed by Par Pharmaceuticals), and Rapamune® (marketed by Wyeth ... - Yahoo! News

Bioprospectors raise ire as they patent more life forms  Jan 20, 2006
Squibb Co. is taken from the bark of the yew tree and Wyeth's kidney transplant drug Rapamune comes from Easter Island soil. Such ... - San Jose Mercury News

NATIVE PEOPLE COLLIDE WITH BIOPROSPECTORS  Jan 21, 2006
...in the breast cancer drug Taxol owned by Bristol-Myers Squibb is taken from the bark of the yew tree, and Wyeth's kidney-transplant drug Rapamune comes from ... - San Jose Mercury News

Bioprospectors feel backlash in Hawaii  Jan 21, 2006
Squibb Co. is taken from the bark of the yew tree and Wyeth’s kidney transplant drug Rapamune comes from Easter Island soil. Such ... - MSNBC

ELAN AND ENTREMED EXECUTE LICENSE AGREEMENT  Jan 10, 2006
United States using Elan's nanocrystal technology include TriCor (marketed by Abbott), Megace ES (marketed by Par Pharmaceuticals), and Rapamune (marketed by ... - Small Times

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional